Literature DB >> 24063841

Relation of conjugated bilirubin concentrations to the presence of coronary artery calcium.

Ki-Chul Sung1, Jinho Shin, Young-Hyo Lim, Sarah H Wild, Christopher D Byrne.   

Abstract

Whether conjugated bilirubin concentration, resulting from hepatic UDP-glucuronosyltransferase 1 A1 activity, is associated with cardiovascular disease is unknown. Our aim was to investigate the relation between serum conjugated bilirubin concentrations and coronary artery calcium score (CACS) as a measure of preclinical atherosclerosis. Data were analyzed from an occupational cohort of 14,583 subjects who underwent a cardiac computed tomographic estimation of CACS and measurements of risk factors. Logistic regression was used to describe associations between bilirubin concentrations and CACS. The proportion of subjects with a CACS >0 (total: men = 1,351, women = 111) decreased across increasing conjugated bilirubin quartiles (men p <0.001, women p = 0.005). After adjustment for age, gender, waist, systolic blood pressure, smoking, exercise, alcohol, homeostatic model assessment of insulin resistance, glucose, triglyceride, high- and low-density lipoprotein cholesterols, high-sensitivity C-reactive protein, lipoprotein (a), ferritin, fatty liver, cerebrovascular accident, coronary artery disease, hypertension, and diabetes, there was an inverse independent association between conjugated bilirubin and CACS >0 (odds ratio 0.76, 95% confidence interval 0.64 to 0.92, p = 0.004, for top vs bottom quartile). After further adjustment for estimated glomerular filtration rate, the odds ratio was 0.83 (95% confidence interval 0.69 to 0.99), p = 0.04. Exclusion of subjects with a high bilirubin (total >1.3 mg/dl) did not attenuate the association. In conclusion, there was a strong inverse and independent relation between conjugated bilirubin and CACS. The mechanism behind this association is not clear and may not be causal, but the effects of glucuronidation on cardiovascular disease risk should be tested.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24063841     DOI: 10.1016/j.amjcard.2013.08.018

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Association of bilirubin with coronary artery calcification and cardiovascular events in the general population without known liver disease: the Heinz Nixdorf Recall study.

Authors:  Amir A Mahabadi; Nils Lehmann; Stefan Möhlenkamp; Hagen Kälsch; Marcus Bauer; Rainer Schulz; Susanne Moebus; Karl-Heinz Jöckel; Raimund Erbel; Gerd Heusch
Journal:  Clin Res Cardiol       Date:  2014-03-15       Impact factor: 5.460

2.  Association of Serum Bilirubin with SYNTAX Score and Future Cardiovascular Events in Patients Undergoing Coronary Intervention.

Authors:  Chun-Chin Chang; Chien-Yi Hsu; Po-Hsun Huang; Chia-Hung Chiang; Shao-Sung Huang; Hsin-Bang Leu; Chin-Chou Huang; Jaw-Wen Chen; Shing-Jong Lin
Journal:  Acta Cardiol Sin       Date:  2016-07       Impact factor: 2.672

3.  Associations between different bilirubin subtypes and diabetic microvascular complications in middle-aged and elderly individuals.

Authors:  Heng Wan; Hui Zhu; Yuying Wang; Kun Zhang; Yi Chen; Sijie Fang; Fangzhen Xia; Ningjian Wang; Wen Zhang; Yingli Lu
Journal:  Ther Adv Endocrinol Metab       Date:  2020-07-11       Impact factor: 3.565

4.  The prevalence and risk factors of prostatic calcification: an analysis of 68 705 subjects.

Authors:  Zhuang Tang; Xiao-Mei Wu; Qiang Wei; Lin-Na Wu
Journal:  Asian J Androl       Date:  2018 Jul-Aug       Impact factor: 3.285

5.  The associations between serum biomarkers and stenosis of the coronary arteries.

Authors:  Lei Feng; Shiyan Nian; Shu Zhang; Wenbo Xu; Xingfeng Zhang; Dan Ye; Lei Zheng
Journal:  Oncotarget       Date:  2016-06-28

6.  The Relationship between Serum Bilirubin and Elevated Fibrotic Indices among HBV Carriers: A Cross-Sectional Study of a Chinese Population.

Authors:  Min Du; Shanshan Zhang; Lin Xiao; Yanyan Xu; Peiyi Liu; Yuhan Tang; Sheng Wei; Mingyou Xing; Xiaoping Miao; Ping Yao
Journal:  Int J Mol Sci       Date:  2016-12-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.